Department of Internal Medicine I, University Hospital Wuerzburg, Würzburg, Germany.
Br J Pharmacol. 2010 Jul;160(5):1243-51. doi: 10.1111/j.1476-5381.2010.00767.x.
Our recent experiments demonstrated that the Sphingosine-1-phosphate (S1P) receptor agonist FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride) improves recovery of function after myocardial ischaemia-reperfusion ex vivo. Therefore, we tested the hypothesis that pharmacological post-conditioning with FTY720 reduces infarct size after myocardial ischaemia-reperfusion in vivo.
Myocardial ischaemia was induced in Wistar rats by ligation of the left coronary artery for 45 min. FTY720 (0.5 mg kg(-1)) was applied i.p. either once, before reperfusion, or twice, 24 h before myocardial ischaemia and before reperfusion. After 24 h reperfusion, we determined infarct size by triphenyltetrazolium chloride staining and granulocyte infiltration by immunohistochemistry. Tumour necrosis factor-alpha (TNF)-alpha concentration was determined by elisa. S1P receptor expression was studied by Western blot. Calcium transients were evaluated in Indo-1-loaded cardiomyocytes.
In both groups, FTY720 significantly reduced lymphocyte count in peripheral blood. FTY720 treatment attenuated granulocyte infiltration and TNF-alpha protein expression in reperfused myocardium. However, both treatment regimens were not able to reduce infarct size. FTY720 increased mortality due to induction of fatal ventricular tachyarrhythmias when administered once before reperfusion, but protected against reperfusion arrhythmias when given 24 h prior to ischaemia. Pretreatment selectively down-regulated S1P(1) receptor expression within the myocardium. S1P receptor agonists did not induce calcium deregulation in cardiomyocytes.
FTY720 applied during reperfusion did not reduce infarct size but increased mortality during myocardial ischaemia-reperfusion due to induction of arrhythmias. Pretreatment with FTY720 before ischaemia abrogated the deleterious pro-arrhythmic effects without reducing infarct size.
我们最近的实验表明,鞘氨醇-1-磷酸(S1P)受体激动剂 FTY720(2-氨基-2-[2-(4-辛基苯基)乙基]-1,3-丙二醇盐酸盐)可改善体外心肌缺血再灌注后的功能恢复。因此,我们检验了这样一个假设,即在体内心肌缺血再灌注后,FTY720 的药物后处理可减少梗死面积。
通过结扎左冠状动脉 45 分钟诱导 Wistar 大鼠心肌缺血。FTY720(0.5mgkg-1)腹腔注射,一次,在再灌注前,或两次,在心肌缺血前 24 小时和再灌注前。再灌注 24 小时后,我们通过三苯基四氮唑氯化物染色法测定梗死面积,并通过免疫组织化学法测定粒细胞浸润。通过 ELISA 测定肿瘤坏死因子-α(TNF)-α浓度。通过 Western blot 研究 S1P 受体表达。用 Indo-1 负载的心肌细胞评估钙瞬变。
在两组中,FTY720 显著降低了外周血中的淋巴细胞计数。FTY720 治疗减轻了再灌注心肌中的粒细胞浸润和 TNF-α蛋白表达。然而,两种治疗方案都不能减少梗死面积。FTY720 单次再灌注前给药会导致致命性室性心动过速的诱导,从而增加死亡率,但在缺血前 24 小时给药可预防再灌注心律失常。预处理选择性地下调了心肌中的 S1P(1)受体表达。S1P 受体激动剂不会诱导心肌细胞中的钙失调。
FTY720 在再灌注期间应用并未减少梗死面积,但由于诱导心律失常,在心肌缺血再灌注期间增加了死亡率。缺血前给予 FTY720 预处理可消除有害的致心律失常作用,而不减少梗死面积。